Mylan settles Viagra patent litigation with Pfizer

The Pfizer logo is seen at their world headquarters in New York(Reuters) – Drugmaker Mylan N.V said it settled a patent litigation with Pfizer Inc related to Viagra, paving the way for the launch of the drug's generic version in the United States once approved. Mylan said on Monday that the settlement would allow it to launch Sildenafil Citrate by December 2017, or sooner under certain conditions, subject to approval by the U.S. Food and Drug Administration. Pfizer's patent for Viagra, used to treat erectile dysfunction, expires in 2020. Mylan did not disclose other terms of the settlement, citing confidentiality, and added that the settlement and license agreement was subject to review by the U.S. Department of Justice and the Federal Trade Commission.



Sexual Health News Headlines – Yahoo! News